The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer

Table 3

Patient characteristics in relation to CEA and CA19-9 levels.

(a)

Characteristics	CEA		value
	>35%	≤35%
Gender			1.000
Male	10	32
Female	8	23
Primary tumor			0.022
Colon	7	38
Rectum	11	15
No. of metastatic sites
1	10	49
>1	8	6
Only liver	2	30
Only lung	3	14
Only local abdominal mass	2	3
Only peritoneum	3	2

(b)

Characteristics	CA19-9		value
	>28%	≤28%
Gender			0.774
Male	8	34
Female	7	24
Primary tumor			0.075
Colon	6	39
Rectum	9	19
No. of metastatic sites
1	8	51
>1	7	7
Only liver	2	30
Only lung	2	15
Only local abdominal mass	2	3
Only peritoneum	2	3

(c)

Characteristics	CEA > 35% & CA19-9 > 28%		value
	Yes	No
Gender			1.000
Male	5	37
Female	4	27
Primary tumor			0.078
Colon	3	42
Rectum	6	22
No. of metastatic sites
1	5	54
>1	4	10
Only liver	1	31
Only lung	1	16
Only local abdominal mass	1	4
Only peritoneum	2	3